Unknown

Dataset Information

0

The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.


ABSTRACT: The receptor for the urokinase-type plasminogen activator (uPAR) is a widely recognized master regulator of cell migration and uPAR88-92 is the minimal sequence required to induce cell motility and angiogenesis by interacting with the formyl peptide receptor type 1 (FPR1). In this study, we present evidence that the cyclization of the uPAR88-92 sequence generates a new potent inhibitor of migration, and extracellular matrix invasion of human osteosarcoma and chondrosarcoma cells expressing comparable levels of FPR1 on cell surface. In vitro, the cyclized peptide [SRSRY] prevents formation of capillary-like tubes by endothelial cells co-cultured with chondrosarcoma cells and trans-endothelial migration of osteosarcoma and chondrosarcoma cells. When chondrosarcoma cells were subcutaneously injected in nude mice, tumor size, intra-tumoral microvessel density and circulating tumor cells in blood samples collected before the sacrifice, were significantly reduced in animals treated daily with i.p-administration of 6 mg/Kg [SRSRY] as compared to animals treated with vehicle only. Our findings indicate that [SRSRY] prevents three key events occurring during the metastatic process of osteosarcoma and chondrosarcoma cells: the extracellular matrix invasion, the formation of a capillary network and the entry into bloodstream.

SUBMITTER: Ingangi V 

PROVIDER: S-EPMC5342356 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4418665 | BioStudies
1000-01-01 | S-EPMC5503633 | BioStudies
2013-01-01 | S-EPMC3540013 | BioStudies
2013-01-01 | S-EPMC3706611 | BioStudies
1000-01-01 | S-EPMC6147788 | BioStudies
2010-01-01 | S-EPMC2837621 | BioStudies
1000-01-01 | S-EPMC4694896 | BioStudies
1000-01-01 | S-EPMC4381593 | BioStudies
2013-01-01 | S-EPMC3743157 | BioStudies
2013-01-01 | S-EPMC3851317 | BioStudies